Subsequent targeting has proven critical; a neoadjuvant CCR2 inhibitor (PF‐04136309) depletes TAMs, inhibiting GOLM1‐mediated colorectal cancer (CRC) metastasis in residual tumor cells [162, 163]. This evidence concerns the gene CCR2 and neoplasm.